Cirina
GRAIL is a healthcare company focused on early cancer detection through its multi-cancer early detection (MCED) test, Galleri®. The company's mission is to detect cancer early when it can be cured, aiming to change the trajectory of cancer mortality. GRAIL's technology analyzes cell-free DNA in blood to identify signals from many types of cancer, including those without recommended screening. The company has conducted large-scale clinical studies like PATHFINDER and has partnered with healthcare systems and organizations to expand access and research. GRAIL's business model involves offering its diagnostic tests to healthcare providers and exploring collaborations with biopharmaceutical companies for research applications.
Cirina
GRAIL is a healthcare company focused on early cancer detection through its multi-cancer early detection (MCED) test, Galleri®. The company's mission is to detect cancer early when it can be cured, aiming to change the trajectory of cancer mortality. GRAIL's technology analyzes cell-free DNA in blood to identify signals from many types of cancer, including those without recommended screening. The company has conducted large-scale clinical studies like PATHFINDER and has partnered with healthcare systems and organizations to expand access and research. GRAIL's business model involves offering its diagnostic tests to healthcare providers and exploring collaborations with biopharmaceutical companies for research applications.
TL;DR
Company: Cirina (Cirina Limited)
Outcome: Combined into GRAIL in 2017
Focus: Blood‑plasma tests for early cancer detection (cfDNA / methylation)
Founders: Dennis Lo, Rossa Chiu, Allen Chan
Lead investor: Decheng Capital
Company Overview
Problem Domain
Early detection of cancer via minimally invasive blood tests
Industry
Diagnostics / Early cancer detection
Funding Track Record
Last disclosed round closed October 2016
Investor Signal
“Decheng Capital named as lead investor”